QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ na
-- x --
-- x --
-- - --
nm - nm
0
na
13.26M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alphaton-capital-launches-with-100m-ton-acquisition-taps-telegram-ecosystem-brittany-kaiser-appointed-ceo

AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User EcosystemBrittany Kaiser, pionee...

 portage-biotech-and-compedica-entered-a-mutual-subscription-agreement

Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,...

 portage-biotech-stock-surges-as-it-prepares-for-human-trial

Portage Biotech stock jumped after new PORT-7 data showed enhanced immune response and plans advanced for combined A2A and A2B ...

Core News & Articles
Market-Moving News for April 28th
04/28/2025 11:28:43

PRTG: 81% | Portage Biotech Reports Confirmatory Preclinical Efficacy Data For PORT-7 (TT-4). The New Data In A Murine Mesothel...

 portage-biotech-reports-confirmatory-preclinical-efficacy-data-for-port-7-tt-4-the-new-data-in-a-murine-mesothelioma-model-demonstrated-single-agent-activity-for-port-7-that-was-superior-to-treatment-with-single-agent-anti-pd1-antibody

Combining PORT-6 and PORT-7 for a More Comprehensive Immunotherapy ApproachIn parallel, Portage is advancing the dose escalatio...

 why-is-portage-biotech-stock-skyrocketing-friday

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION